Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
resources:fluoroquinolones [2018/12/14 01:05]
bpaddock Add European Medicines Agency info.
resources:fluoroquinolones [2018/12/14 02:15]
bpaddock Updated PRAC formating.
Line 139: Line 139:
 because these patients are at a higher risk of tendon injury. //Since the use of a corticosteroid with a because these patients are at a higher risk of tendon injury. //Since the use of a corticosteroid with a
 fluoroquinolone also increases this risk, combined use of these medicines should be avoided//​...</​blockquote>​ --  fluoroquinolone also increases this risk, combined use of these medicines should be avoided//​...</​blockquote>​ -- 
-//​[[https://​www.ema.europa.eu/​en/​medicines/​human/​referrals/​quinolone-fluoroquinolone-containing-medicinal-products|Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics]]//​ [[[https://​www.ema.europa.eu/​documents/​referral/​quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf|PDF]]].+//​[[https://​www.ema.europa.eu/​en/​medicines/​human/​referrals/​quinolone-fluoroquinolone-containing-medicinal-products|Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics]]//​ [ [[https://​www.ema.europa.eu/​documents/​referral/​quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf|PDF]] ].
  
 October 5th 2018: October 5th 2018:
Line 149: Line 149:
 The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of fluoroquinolone and quinolone antibiotics (used by mouth, injection or inhalation) following a review of disabling and potentially long-lasting side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended restricting the use of fluoroquinolone and quinolone antibiotics (used by mouth, injection or inhalation) following a review of disabling and potentially long-lasting side effects reported with these medicines. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018.
  
-Very rarely [**//__THIS IS NOT TRUE, NOT RARE AT ALL__//], patients treated with fluoroquinolone or quinolone antibiotics have suffered long-lasting and disabling side effects, mainly involving muscles, tendons and bones and the nervous system. ​  +Very rarely [**//__THIS IS NOT TRUE, NOT RARE AT ALL__//**], patients treated with fluoroquinolone or quinolone antibiotics have suffered long-lasting and disabling side effects, mainly involving muscles, tendons and bones and the nervous system. ​  
  
-Following its evaluation of these side effects, the PRAC has recommended that some medicines, including all those that contain a quinolone antibiotic, should be removed from the market. This is because they are authorised only for infections that should no longer be treated with this class of antibiotics.+<​blockquote>​**Following its evaluation of these side effects, the PRAC has recommended that some medicines, including all those that contain a //quinolone antibiotic//, should be removed from the market. This is because they are authorised only for infections that should no longer be treated with this class of antibiotics.**</​blockquote>​
  
 The PRAC recommended that the remaining fluoroquinolone antibiotics should: The PRAC recommended that the remaining fluoroquinolone antibiotics should:
Line 162: Line 162:
   * be used with caution especially for the elderly [They should not be used in the elderly at all], patients with kidney problems, patients who have had an organ transplantation or those who are being treated with a systemic corticosteroid. These patients are at higher risk of tendon injury caused by fluoroquinolone and quinolone antibiotics.   * be used with caution especially for the elderly [They should not be used in the elderly at all], patients with kidney problems, patients who have had an organ transplantation or those who are being treated with a systemic corticosteroid. These patients are at higher risk of tendon injury caused by fluoroquinolone and quinolone antibiotics.
  
-The PRAC also recommended that healthcare professionals should advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or bones (such as inflamed or torn tendon, muscle pain or weakness, and joint pain or swelling) or the nervous system (such as feeling pins and needles, tiredness, depression, confusion, suicidal thoughts, sleep disorders, vision and hearing problems, and altered taste and smell).</​blockquote>​ -- [[https://​www.ema.europa.eu/​en/​news/​fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use|https://​www.ema.europa.eu/​en/​news/​fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use]]+The PRAC also recommended that healthcare professionals should advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or bones (such as inflamed or torn tendon, muscle pain or weakness, and joint pain or swelling) or the nervous system (such as feeling pins and needles, tiredness, depression, confusion, suicidal thoughts, sleep disorders, vision and hearing problems, and altered taste and smell).</​blockquote>​ -- [[https://​www.ema.europa.eu/​en/​news/​fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use|https://​www.ema.europa.eu/​en/​news/​fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use]] [ [[https://​www.ema.europa.eu/​documents/​press-release/​fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use_en.pdf|PDF]] ]
  
 June 13th 2018: June 13th 2018: